<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684498</url>
  </required_header>
  <id_info>
    <org_study_id>TJ-AMI-NI</org_study_id>
    <nct_id>NCT04684498</nct_id>
  </id_info>
  <brief_title>Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients</brief_title>
  <official_title>An Open-label Study to Evaluate the Efficacy of Neuraminidase Inhibitor Treatment in ST-Elevation Myocardial Infarction (STEMI) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuraminidase-1 can cause the removal of terminal sialic acid residues from the cell surface&#xD;
      or serum sialyloconjugates. The level of Neu5Ac was positively related to the activity of&#xD;
      neuraminidase-1. Elevation of Neu5Ac was observed in myocardial ischemia animal model, as&#xD;
      well as patients with coronary artery disease. It is interesting to note that Neu5Ac and its&#xD;
      regulatory enzyme neuraminidase-1 seem to play a key role in triggering myocardial ischemic&#xD;
      injury. Oseltamivir, a structural mimic of sialic acid, was widely used as anti-influenza&#xD;
      drug. It suppressed neuraminidase-1 activity in the heart. Targeting neuraminidase-1 may&#xD;
      represent a new therapeutic intervention for coronary artery disease. This project seeks to&#xD;
      identify whether neuraminidase inhibitor (Oseltamivir) treatment could decrease the&#xD;
      myocardial infarct size in STEMI patients and improve clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size at 1 week</measure>
    <time_frame>1 week</time_frame>
    <description>Myocardial infarct size at 1 week after acute myocardial infarction (quantified by Gadolinium-enhanced MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size</measure>
    <time_frame>1 week</time_frame>
    <description>Myocardial infarct size under the curve of creatine kinase-MB (CK-MB) and hypersensitive troponin I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size based on culprit vessel with TIMI 0-1 blood flow</measure>
    <time_frame>1 week</time_frame>
    <description>Evaluated by coronary angiography and CMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of viable myocardium and ratio of myocardial reperfusion</measure>
    <time_frame>1 week</time_frame>
    <description>The proportion of viable myocardium and reperfusion was determined by the range of abnormal enhancement of gadolinium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite end point at 1 week</measure>
    <time_frame>1 week</time_frame>
    <description>A composite end point of cardiogenic shock, cardiac death, malignant arrhythmia, and resuscitated cardiac arrest (including ventricular fibrillation) at 1 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarct size at 3 month</measure>
    <time_frame>3 month</time_frame>
    <description>Myocardial infarct size at 3 month after acute myocardial infarction (quantified by Gadolinium-enhanced MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite end point at 6 month</measure>
    <time_frame>6 month</time_frame>
    <description>Composite end point at 6 month, including all-cause death, reinfarction, heart failure after myocardial infarction, and rehospitalization of unstable angina at 6 month.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">382</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Tamiflu (Oseltamivir Phosphate Capsules)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized STEMI treatment + oseltamivir phosphate capsule (75mg, 2 times/day, 7days, oral)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standardized STEMI treatment + no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir phosphate capsules</intervention_name>
    <description>Treatment group vs. Control group</description>
    <arm_group_label>Tamiflu (Oseltamivir Phosphate Capsules)</arm_group_label>
    <arm_group_label>no intervention</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 18 and 75, regardless of gender;&#xD;
&#xD;
          2. STEMI should be diagnosed by two attending physicians or above, including history,&#xD;
             clinical symptoms and signs;&#xD;
&#xD;
          3. Participate voluntarily and sign informed consent, and can be followed up for more&#xD;
             than one month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to oseltamivir;&#xD;
&#xD;
          2. Creatinine clearance rate less than 60%;&#xD;
&#xD;
          3. Severe liver insufficiency;&#xD;
&#xD;
          4. Female patients who have or plan to become pregnant;&#xD;
&#xD;
          5. Life expectancy less than one year;&#xD;
&#xD;
          6. Patients refused to comply with the requirements of this study;&#xD;
&#xD;
          7. According to the discretion of investigator, the patient was unable to complete the&#xD;
             study or comply with the requirements of the study (for administrative or other&#xD;
             reasons).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dao Wen Wang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luyun Wang, M.D., Ph.D</last_name>
    <phone>+86-02783665548</phone>
    <email>wangluyun2004@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiangang Jiang, M.D., Ph.D</last_name>
    <phone>+86-02783665548</phone>
    <email>jiangjg618@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luyun Wang, M.D., Ph.D.</last_name>
      <phone>+86-02783665548</phone>
      <email>wangluyun2004@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiangang Jiang, M.D., Ph.D.</last_name>
      <phone>+86-02783665548</phone>
      <email>jiangjg618@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji Hospital</investigator_affiliation>
    <investigator_full_name>Dao Wen Wang</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

